// App-Quantinova.ai

5042 : Targeting the ERK5 and ERK1/2 pathways simultaneously induces mesenchymal to epithelial transition in TNBC

Researchers

Presenter

  • Akshita Bhatt

Principal Investigators

  • Thomas Wright

  • Van Barnes

  • Suravi Chakrabarty

  • Patrick Flaherty

  • Matthew Burow

  • Jane Cavanaugh

Medical Centers

  • Duquesne University, Pittsburgh, PA

  • Marshall University Joan C. Edwards School of Medicine, Huntington, WV

  • National Cancer Institute, Bethesda, MD

  • KU Leuven, United Kingdom

  • Tulane University, New Orleans, LA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Cervical cancer

  • Breast cancer

Biomarkers

  • Mitogen-activated protein kinase

  • Mitogen-activated protein kinase 3

  • Dual specificity mitogen-activated protein kinase kinase 1

  • B-Raf proto-oncogene, serine/threonine kinase

  • Cadherin 1

  • erb-b2 receptor tyrosine kinase 2

  • Extracellular signal-regulated kinase

  • Solute Carrier Family 22 Member 3

  • Zinc finger E-box binding homeobox 1

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • Doxorubicin

  • XMD892

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved